| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6801890 | Journal of Substance Abuse Treatment | 2018 | 4 Pages |
Abstract
XR-NTX did not significantly increase rates of healthcare utilization compared to TAU. Provider concerns regarding healthcare utilization should not preclude the consideration of XR-NTX as therapy for opioid use disorders.
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
William E. III, Donna Wilson, Niels Rathlev, Joshua D. Lee, Michael Gordon, Edward V. Nunes, Charles P. O'Brien, Peter D. Friedmann,